NR1D1 is one of those subjects where the details matter more than the headlines. This page pulls together the background, the mechanisms, and the practical points readers ask about most.
Last reviewed on 2025-09-24. Where a claim depends on a specific study, the study is described rather than over-claimed.
Laboratory identification of SR9009 typically relies on chromatographic separation coupled to mass spectrometry, often with ultraviolet detection as a secondary check. Nuclear magnetic resonance spectroscopy can confirm molecular structure when a reference standard is available. Because many suppliers sell the compound as a research chemical, independent identity testing is important for experimental reproducibility. A single retention time is not sufficient proof of identity, especially when related compounds may be present. Purity assessments usually report a percentage based on area normalization.
SR9009 is generally described as poorly soluble in water and more soluble in organic solvents such as dimethyl sulfoxide and ethanol. Stock solutions are commonly prepared in an organic solvent before dilution into an aqueous buffer or vehicle. Precipitation can occur if the organic fraction is reduced too quickly or if the final concentration exceeds the compound's solubility limit. Sonication or gentle warming may aid dissolution in some protocols, but excessive heat can promote degradation. Container material and pH can also influence observed solubility.
For long-term storage, SR9009 is typically kept as a solid at low temperature, protected from moisture and light. Desiccated conditions limit hydrolysis, while opaque containers reduce photochemical breakdown. Solutions are less stable than solids and are often stored frozen in aliquots to avoid repeated freeze-thaw cycles. Stability data are not standardized across all suppliers, so users should rely on certificate-of-analysis information when available. Degradation may appear as color change, precipitate, or decreased chromatographic purity.
SR9009 is a synthetic small molecule developed as an agonist of the nuclear receptors REV-ERBα (NR1D1) and REV-ERBβ (NR1D2). These receptors help regulate circadian rhythms and metabolic gene expression. In cell and animal studies, SR9009 alters transcription of genes involved in lipid metabolism, inflammation, and mitochondrial function. It is not an approved medicine, and its pharmacological profile in humans remains largely uncharacterized. The compound is frequently discussed in the context of circadian biology and metabolic research rather than clinical use.
Preclinical reports have linked SR9009 to improved endurance and altered energy expenditure in rodents. Such findings have prompted interest in whether REV-ERB activation can influence skeletal muscle metabolism. However, the reported effects depend on dose, route, and experimental model, and replication across laboratories is limited. Human trials have not established comparable outcomes, so claims about exercise performance remain speculative. The absence of controlled human data is a central limitation in interpreting these observations.
The mechanism of action involves binding to REV-ERB receptors and recruiting corepressor complexes, which represses target gene transcription. This contrasts with many nuclear receptor agonists that activate transcription. Downstream effects may include changes in autophagy, mitochondrial biogenesis, and lipid handling, but the precise pathways remain an active area of study. Whether these molecular events translate into meaningful physiological effects in humans is unresolved. Most evidence comes from cultured cells and rodent models rather than human participants.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Visual inspection is not sufficient for identity. |
| Solubility | Soluble in DMSO and ethanol | Low solubility in water; stock solutions use organic solvent. |
| Storage | -20°C, desiccated, protected from light | Limits hydrolysis and photodegradation. |
| Analytical method | HPLC-UV/MS | Used for identity and purity assessment. |
| Synonyms | SR9009, Stenabolic | Naming varies by supplier. |
At the molecular level, SR9009 binds the ligand-binding domain of REV-ERB and strengthens recruitment of corepressor proteins such as NCoR and HDAC3. This increases repression of target genes, including Bmal1 and other clock-controlled and metabolic genes. In rodent studies, such changes have been linked to altered lipid handling, glucose metabolism, and energy expenditure. The precise chain of events between receptor binding and whole-body effects remains an active area of research. Findings in animals do not automatically translate to humans.
Laboratory studies often administer SR9009 by injection because oral absorption appears poor in rodents. Reported pharmacokinetic properties include rapid metabolism and low systemic exposure after oral dosing. Human pharmacokinetic data are sparse, so absorption, distribution, metabolism, and excretion in people are not well defined. Some research explores related REV-ERB compounds with improved drug-like properties. Regulatory approval for any REV-ERB agonist as a human medicine has not been granted to date.
Preclinical reports describe effects on exercise endurance, mitochondrial content, and lipid profiles in rodents, but these findings come from specific experimental conditions. Many studies use high doses or delivery methods that may not translate directly to human use. SR9009 has been reported to have low oral bioavailability and a short half-life, which complicates interpretation of oral dosing studies. It is not established as safe or effective for any indication. Literature discussions often separate its pharmacological mechanism from unverified claims made in fitness and supplement markets.
SR9009 is a synthetic small molecule studied as an agonist of the nuclear receptors REV-ERBα and REV-ERBβ. It is not an approved medicine and has no established human therapeutic use. The compound appears in scientific literature as a tool for probing circadian and metabolic regulation. Online sellers often label it as a research chemical, sometimes using the nickname Stenabolic. Its chemical identity is distinct from selective androgen receptor modulators, stimulants, and peroxisome proliferator-activated receptor delta agonists. Researchers use it mainly in cell and animal experiments.
At the molecular level, SR9009 binds REV-ERBα and REV-ERBβ and alters their repressive activity on target genes. These nuclear receptors help regulate the circadian clock, lipid synthesis, glucose metabolism, and inflammatory pathways. By changing transcription, the compound can shift the timing or magnitude of downstream metabolic processes in model systems. It does not act through androgen receptors or adenosine receptors, which distinguishes it from several substances sold for athletic performance. Whether the same transcriptional changes occur in humans at tolerable exposures remains an open question because controlled human studies are lacking.
== Effects upon EU policy == The EU often applies the precautionary principle very stringently in regards to food safety. The precautionary principle means that in a case of scientific uncertainty, the government may take appropriate measures proportionate to the potential risk (EC Regulation 178/2002). In 1996, the EU banned imported beef from the US and continued to do so after the 2003 Mad Cow scare. A more sophisticated risk assessment found there to be insufficient risk to ban certain hormones, but continued to ban others. Labeling of meat was another option, however warnings were also insufficient because of the criteria specified in the SPS (Sanitary and Phyto-Sanitary agreement). This agreement allows members to use scientifically based measures to protect public health. Most specifically the Equivalence provision in Article 4 which states the following: "an importing country must accept an SPS measure which differs from its own as equivalent if the exporting country’s measure provides the same level of health or environmental protection." Therefore, although the EU is a strong proponent of labels and banning meat that contains growth hormones, requiring the US to do the same would have violated this agreement.
Psylocke is the alias of two connected characters appearing in American comic books published by Marvel Comics, commonly in association with the X-Men. Both characters are depicted as mutants, a subspecies of humans born with an "X-gene" that grants superhuman abilities. In the primary continuity of the Marvel Universe, the first and best-known incarnation of Psylocke is Betsy Braddock (created by Chris Claremont and Herb Trimpe), a British telepath who was introduced as a supporting character for her twin brother Brian in 1976. Betsy adopts the codename "Psylocke" upon joining the X-Men in 1986, and three years later takes on the appearance of a Japanese woman and the abilities of a ninja in a story written by Claremont and illustrated by Jim Lee. This redesign was retroactively revealed in 1993 as the result of a body swap with the ninja assassin Kwannon (created by Fabian Nicieza and Andy Kubert). Following 29 years of publication history, both women were returned to their respective bodies, and Betsy assumed the mantle of Captain Britain from her brother while Kwannon became the second Psylocke. The Ultimate Universe features two versions of Psylocke: Sai and Kanon Sainouchi (both created by Peach Momoko). In addition to their presence in numerous X-related team titles over the decades, both iterations of Psylocke have been featured in various limited series and one-shots. In 1997, Betsy Braddock, as Psylocke, appeared in the 4-issue team-up series Psylocke and Archangel: Crimson Dawn.
==== Conducting Wire ==== Due to Graphene's high electrical and thermal conductivity, mechanical strength, and corrosion resistance, one potential application is in high-power energy transmission. Copper wire has long been used for power transmission for its high conductivity, ductility, and low costs. However, traditional wire fails to meet the transmission requirements of many new technologies. Thermally dependent resistivity in mesoscopic copper wire limits efficiency and current carrying capacity in small-scale electronics. Additionally, copper wire exhibits internal failure by electromigration at high current density, limiting miniaturization of wire. Copper's high weight and low temperature oxidation also limit its applications in high-power transmission. Increasing demand for high ampacity transmission in electronics and electric vehicle applications necessitate improvements in conductor technology. Graphene-copper composite conductors are a promising alternative to standard conductors in high-power applications. In 2013, researchers demonstrated a one-hundred-fold increase in current carrying capacity with carbon nanotube-copper composite wires when compared to traditional copper wire. These composite wires exhibited a temperature coefficient of resistivity an order of magnitude smaller than copper wires, an important feature for high load applications.
Sources: en.wikipedia.org
=== Silica === Silica naturally leaches from glass walls and enters water supplies. Dissolved silica, in the form of the silicate anion, can be removed through reverse osmosis or anion exchange. Solid, colloidal silica can be removed via ultrafiltration with or without coagulation to increase particle size.
=== Box office === Dredd earned $27.6 million from markets outside of North America and $13.4 million from North America, for a total of $41 million. In the UK, Dredd grossed £1.05 million ($1.7 million) from 415 cinemas during its opening weekend. This made it the weekend's number-one film, the first film restricted to audiences over 18 years of age to do so since Saw 3D in 2010. In its second weekend, the film placed number five, earning £769,381. Dredd was primarily shown in 3D in the UK, and 2D screenings were notoriously limited as the distributor denied cinemas' requests for 2D prints; the decision was considered to have limited the film's audience where 2D was their preferred format. Dredd earned a total of $6.9 million in the UK. In North America, pre-release tracking estimated that the film would gross between $8 and $10 million during its opening weekend based on its adult rating and the poor reputation of the 1995 adaptation. The film earned $2.2 million on its opening day and finished the weekend in sixth place, grossing $6.3 million from 2,506 cinemas—an average of $2,514 per cinema. The largest demographic of the opening weekend audience was over the age of 25 (69%) and male (75%). The film's North American run ended on 1 November 2012, after 42 days. Outside of the UK and North America, Dredd had its most successful total gross takings in China ($4.5 million), Russia ($4 million), and Australia ($2 million). Urban criticised the film's marketing campaign, saying that the film had "zero audience awareness. Nobody knew the movie was being released.
==== Comprehensive metabolic panel ==== Comprehensive metabolic panel (CMP) - 14 tests - above BMP plus total protein, albumin, alkaline phosphatase (ALP), alanine amino transferase (ALT), aspartate amino transferase (AST), bilirubin.
=== Centrally active === These drugs are used mainly as antidotes to reverse opioid overdose and in the treatment of alcohol dependence and opioid dependence (by blocking the effects, namely euphoria, of opioids so as to discourage abuse).
Sources: en.wikipedia.org
Liquid chromatography with mass spectrometry is a common approach. Ultraviolet detection and nuclear magnetic resonance can support identification when suitable standards are available.
The solid is generally kept cold, dry, and protected from light. Solutions are often frozen in single-use aliquots to reduce repeated freeze-thaw cycles.
It indicates a material sold for laboratory study, not for human use. The label does not guarantee pharmaceutical purity, sterility, or regulatory approval.
It is a synthetic compound that acts as an agonist at REV-ERBα and REV-ERBβ. It is used mainly as a research chemical to study circadian and metabolic pathways. It is not approved for human therapeutic use.